How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/amlodipine-losartan-potassium-and-hydrochlorothiazide.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Amlodipine, losartan potassium and hydrochlorothiazide — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Amlodipine, losartan potassium and hydrochlorothiazide (Amlodipine, losartan potassium and hydrochlorothiazide) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antihypertensive combination (calcium channel blocker + angiotensin II receptor blocker + thiazide diure

phase 3 Antihypertensive combination (calcium channel blocker + angiotensin II receptor blocker + thiazide diuretic) L-type calcium channels, AT1 angiotensin II receptor, sodium-chloride cotransporter Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Amlodipine, losartan potassium and hydrochlorothiazide (Amlodipine, losartan potassium and hydrochlorothiazide) — Shanghai WiseGain Medical Devices Co., Ltd.. This triple-combination antihypertensive reduces blood pressure through three complementary mechanisms: calcium channel blockade, angiotensin II receptor antagonism, and thiazide diuresis.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Amlodipine, losartan potassium and hydrochlorothiazide TARGET	Amlodipine, losartan potassium and hydrochlorothiazide	Shanghai WiseGain Medical Devices Co., Ltd.	phase 3	Antihypertensive combination (calcium channel blocker + angiotensin II receptor blocker + thiazide diuretic)	L-type calcium channels, AT1 angiotensin II receptor, sodium-chloride cotransporter
Amlodipine/Losartan/Chlorthalidone	Amlodipine/Losartan/Chlorthalidone	Hanmi Pharmaceutical Company Limited	marketed	Antihypertensive combination (calcium channel blocker + angiotensin II receptor blocker + thiazide diuretic)	L-type calcium channels, AT1 angiotensin II receptor, sodium-chloride cotransporter

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antihypertensive combination (calcium channel blocker + angiotensin II receptor blocker + thiazide diuretic) class)

Hanmi Pharmaceutical Company Limited · 1 drug in this class
Shanghai WiseGain Medical Devices Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Amlodipine, losartan potassium and hydrochlorothiazide — Competitive Intelligence Brief. https://druglandscape.com/ci/amlodipine-losartan-potassium-and-hydrochlorothiazide. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab